Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

CalcalistHealth

Weight Loss Drug Revolution Reshapes Health Industry, Says Altman CEO

Translated & summarized from Calcalist by baba

BusinessCharged tone

Hebrew · 1 newsroom

David Gordon, CEO of Israel's leading dietary supplement company Altman, stated that new weight loss drugs are revolutionizing the health industry, similar to AI. Altman has launched a new product line to address the side effects of these drugs. Gordon emphasized the company's focus on science-based products and professional marketing, differentiating them from online competitors. Altman plans to expand into women's health and medical devices, positioning itself as a broader pharmaceutical company.

The story in 5 lines · by baba

  • Altman CEO David Gordon compares weight loss drug impact to AI revolution, changing consumer habits.
  • Altman launched GL-Plex supplements to address side effects of new obesity medications.
  • Approximately 400,000 Israelis use weight loss injections, with significant future growth expected.
  • Altman focuses on science-based products and professional marketing, not social media influencers.
  • The company plans to expand into women's health, medical devices, and longevity products.

David Gordon, CEO of Altman, Israel's leading dietary supplement company, likens the impact of new weight loss drugs like Ozempic and Wegovy to the AI revolution, stating they are fundamentally changing consumer behavior across food, pharmaceuticals, and consumption habits. Altman, which holds an estimated 19% of Israel's NIS 1.5 billion supplement market, launched a new line of supplements called GL-Plex three months ago to address the side effects of these obesity medications. Gordon emphasized that obesity is a disease and that these drugs, used by approximately 400,000 Israelis with expectations of significant growth due to upcoming oral formulations, are creating new needs in the market.

Gordon explained that while these drugs help with weight loss by affecting satiety and slowing gastric emptying, they can cause side effects such as nausea, constipation, diarrhea, muscle mass loss, and vitamin deficiencies. Altman's GL-Plex line, including a specialized multivitamin and a probiotic for digestive issues, aims to fill this gap. The company is marketing these products directly to family doctors and pharmacists, positioning them as non-prescription items requiring professional guidance.

Altman, owned by the Kibbutz Me'anot group, differentiates itself by focusing on science-based products and professional marketing channels rather than social media influencers. Gordon highlighted the company's commitment to quality, including strict temperature control throughout the supply chain and professional advice from dietitians, justifying potentially higher prices compared to international online retailers like iHerb. He noted that while iHerb offers competitive pricing, Altman focuses on researched, high-quality ingredients and a robust support system.

Regarding market competition, Gordon acknowledged the challenge posed by private labels from health maintenance organizations (HMOs) and pharmacy chains like Super-Pharm, but asserted Altman's strong market position. He also addressed the 'What's Good for Europe is Good for Israel' reform, stating it increased costs for manufacturers due to the need to switch to European facilities and higher raw material prices, preventing immediate price reductions for consumers.

Looking ahead, Gordon expressed Altman's ambition to expand beyond dietary supplements into areas like medical devices and women's health, including longevity products. He confirmed that while Altman is primarily an importer, it actively researches and develops its unique formulations, leveraging the financial backing and broader strategic knowledge of its parent company, Me'anot.

CalcalistOther · Tel Aviv

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

Mentioned

Open the Wire